Estrogen patches are out of stock. Demand spiked. Supply didn't. Manufacturers say they need a year to fix it. Maybe longer.
This is what happens when pharmaceutical companies spend decades optimizing just-in-time inventory for a product category they assumed would stay predictable. Menopause existed yesterday. It exists today. Shockingly, it will exist tomorrow. Yet here we are, treating a biological certainty like it's a flash mob that appeared out of nowhere.
The shortage started because more women decided menopause symptoms are worth treating instead of just white-knuckling through night sweats until death. Reasonable choice. Manufacturers were not prepared for women to make reasonable choices. They built production capacity assuming most patients would simply suffer in silence like previous generations. Wrong.
Now we've got a year-long backorder on adhesive hormone delivery systems. A full calendar year to scale up production of what is essentially a sticker. These aren't microchips. They're patches. The technological complexity sits somewhere between a Band-Aid and a nicotine patch. And yet.
Retail traders are already scanning for the ticker symbol of whichever generic manufacturer might benefit from the shortage. They will find it. They will buy calls. The stock will move sideways for eleven months while they bleed theta, then dump the day before the shortage actually resolves. They will learn nothing.
The real comedy is that this supply chain failure will get fixed right around the time those same traders discover the next can't-miss shortage play in some other basic medical supply they didn't know existed until a headline told them to care.
Women dealing with menopause symptoms get to wait a year for a patch because production planning failed to account for demand that was literally guaranteed by human biology. Traders get to lose money pretending they understand pharmaceutical supply chains. At least the women have an excuse for the hot flashes.
Photo by Hanen BOUBAHRI on Unsplash
Leave a Comment